10 Pulmonary Hypertension Clinical Trials in Buffalo, NY (2026)

Q: How do I join a clinical trial in Buffalo?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Buffalo research site will contact you.

Recruiting Pulmonary Hypertension Studies in Buffalo

NCT03817502Recruiting

Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia

The purpose of this study is to evaluate the efficacy and safety of cariprazine in the treatment of schizophrenia in the adolescent population....

Buffalo, NY330 participantsGedeon Richter Plc.

View Study Details

NCT04104776Recruiting

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, and preliminary clinical activity of Tulmimetostat as a monotherapy in patients with advanced solid ...

Buffalo, NY275 participantsNovartis Pharmaceuticals

View Study Details

NCT06323044Recruiting

MedSupport Intervention to Identify and Address Barriers to Pediatric Medication Adherence

This clinical trial identifies and addresses barriers to pediatric medication adherence among families of children with acute lymphoblastic leukemia. Pediatric nonadherence (noncompliance) to medicati...

Buffalo, NY150 participantsRoswell Park Cancer Institute

View Study Details

NCT06074666Recruiting

Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence: Study 3

The current study will assess the acceptability and feasibility of the CareMeds intervention with a larger sample (N = 100) across multiple sites in Buffalo, NY, and Atlanta, GA....

Buffalo, NY100 participantsRoswell Park Cancer Institute

View Study Details

NCT05893940Recruiting

Low-Intensity Mechanical Stimulation for Hematologic Malignancy Patients

This clinical trial tests the effect of low-intensity mechanical stimulation (LIMS) vibration therapy in patients with hematologic malignancies. Patients with hematologic malignancies often undergo a ...

Buffalo, NY75 participantsRoswell Park Cancer Institute

View Study Details

NCT07015242Recruiting

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

The purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central N...

Buffalo, NY65 participantsJuno Therapeutics, Inc., a Bristol-Myers Squibb Company

View Study Details

NCT04150497Recruiting

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The...

Buffalo, NY52 participantsCellectis S.A.

View Study Details

NCT07121946Recruiting

This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma

This study is a first-in-human (FIH), Phase 1, multicenter, open-label study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and evaluate the preliminary anti-tumor activity...

Buffalo, NY42 participantsLTZ Therapeutics, Inc.

View Study Details

NCT05651594Recruiting

Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma

This phase II trial tests what effects the addition of propranolol to pembrolizumab and standard chemotherapy (mFOLFOX) may have on response to treatment in patients with esophageal or gastroesophagea...

Buffalo, NY40 participantsRoswell Park Cancer Institute

View Study Details

NCT06798701Recruiting

Virtual Reality for Symptom Management in Patients Undergoing Hematopoietic Stem Cell Transplantation

This clinical trial compares the use of virtual reality to standard care for improving symptom management in patients undergoing hematopoietic stem cell transplantation (HSCT). Significant symptoms ex...

Buffalo, NY28 participantsRoswell Park Cancer Institute

View Study Details

About Pulmonary Hypertension Clinical Trials in Buffalo

Pulmonary hypertension is a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. It can lead to heart failure if untreated. Treatment includes vasodilators, endothelin receptor antagonists, and PDE-5 inhibitors.

There are currently 10 pulmonary hypertension clinical trials recruiting participants in Buffalo, NY. These studies are seeking a combined 1,157 participants. Research is being sponsored by Gedeon Richter Plc., Novartis Pharmaceuticals, Roswell Park Cancer Institute and 3 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Pulmonary Hypertension Clinical Trials in Buffalo — FAQ

Are there pulmonary hypertension clinical trials in Buffalo?

Yes, there are 10 pulmonary hypertension clinical trials currently recruiting in Buffalo, NY. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Buffalo?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Buffalo research site will contact you about next steps.

Are clinical trials in Buffalo free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Buffalo studies also compensate for your time and travel.

What pulmonary hypertension treatments are being tested?

The 10 active trials in Buffalo are testing new therapies including novel drugs, biologics, and treatment approaches for pulmonary hypertension.

Data updated July 13, 2026 from ClinicalTrials.gov